Switch to:
Also traded in: Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.02
SHPGF's Cash to Debt is ranked lower than
98% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. SHPGF: 0.02 )
Ranked among companies with meaningful Cash to Debt only.
SHPGF' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 1.44 Max: No Debt
Current: 0.02
Equity to Asset 0.55
SHPGF's Equity to Asset is ranked lower than
64% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SHPGF: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
SHPGF' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.62 Max: 0.85
Current: 0.55
0.25
0.85
Interest Coverage 42.12
SHPGF's Interest Coverage is ranked lower than
84% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPGF: 42.12 )
Ranked among companies with meaningful Interest Coverage only.
SHPGF' s Interest Coverage Range Over the Past 10 Years
Min: 2.96  Med: 23.74 Max: 55.13
Current: 42.12
2.96
55.13
F-Score: 6
Z-Score: 3.73
M-Score: -2.92
WACC vs ROIC
14.47%
16.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 24.68
SHPGF's Operating margin (%) is ranked higher than
87% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. SHPGF: 24.68 )
Ranked among companies with meaningful Operating margin (%) only.
SHPGF' s Operating margin (%) Range Over the Past 10 Years
Min: -56.61  Med: 20.45 Max: 35.13
Current: 24.68
-56.61
35.13
Net-margin (%) 50.48
SHPGF's Net-margin (%) is ranked higher than
88% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. SHPGF: 50.48 )
Ranked among companies with meaningful Net-margin (%) only.
SHPGF' s Net-margin (%) Range Over the Past 10 Years
Min: -59.59  Med: 15.71 Max: 56.55
Current: 50.48
-59.59
56.55
ROE (%) 37.27
SHPGF's ROE (%) is ranked higher than
87% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. SHPGF: 37.27 )
Ranked among companies with meaningful ROE (%) only.
SHPGF' s ROE (%) Range Over the Past 10 Years
Min: -90.17  Med: 17.82 Max: 49.38
Current: 37.27
-90.17
49.38
ROA (%) 20.63
SHPGF's ROA (%) is ranked higher than
86% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. SHPGF: 20.63 )
Ranked among companies with meaningful ROA (%) only.
SHPGF' s ROA (%) Range Over the Past 10 Years
Min: -37.5  Med: 9.76 Max: 31.55
Current: 20.63
-37.5
31.55
ROC (Joel Greenblatt) (%) 291.49
SHPGF's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. SHPGF: 291.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SHPGF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -396.76  Med: 102.56 Max: 345.44
Current: 291.49
-396.76
345.44
Revenue Growth (3Y)(%) 12.40
SHPGF's Revenue Growth (3Y)(%) is ranked higher than
69% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SHPGF: 12.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SHPGF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.7  Med: 12.70 Max: 26.8
Current: 12.4
-0.7
26.8
EBITDA Growth (3Y)(%) 38.70
SHPGF's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. SHPGF: 38.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SHPGF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.4  Med: 22.80 Max: 38.7
Current: 38.7
-1.4
38.7
EPS Growth (3Y)(%) 56.20
SHPGF's EPS Growth (3Y)(%) is ranked higher than
93% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. SHPGF: 56.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SHPGF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.3  Med: 32.00 Max: 63.3
Current: 56.2
-7.3
63.3
» SHPGF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with SHPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 9.81
SHPGF's P/E(ttm) is ranked higher than
84% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 26.73 vs. SHPGF: 9.81 )
Ranked among companies with meaningful P/E(ttm) only.
SHPGF' s P/E(ttm) Range Over the Past 10 Years
Min: 9.81  Med: 24.92 Max: 74.05
Current: 9.81
9.81
74.05
Forward P/E 10.21
SHPGF's Forward P/E is ranked higher than
74% of the 342 Companies
in the Global Biotechnology industry.

( Industry Median: 16.21 vs. SHPGF: 10.21 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 10.39
SHPGF's PE(NRI) is ranked higher than
86% of the 271 Companies
in the Global Biotechnology industry.

( Industry Median: 31.00 vs. SHPGF: 10.39 )
Ranked among companies with meaningful PE(NRI) only.
SHPGF' s PE(NRI) Range Over the Past 10 Years
Min: 10.39  Med: 22.80 Max: 106.93
Current: 10.39
10.39
106.93
P/B 3.31
SHPGF's P/B is ranked lower than
66% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. SHPGF: 3.31 )
Ranked among companies with meaningful P/B only.
SHPGF' s P/B Range Over the Past 10 Years
Min: 2.22  Med: 5.49 Max: 14.23
Current: 3.31
2.22
14.23
P/S 4.63
SHPGF's P/S is ranked higher than
70% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 9.03 vs. SHPGF: 4.63 )
Ranked among companies with meaningful P/S only.
SHPGF' s P/S Range Over the Past 10 Years
Min: 2.25  Med: 4.44 Max: 9.34
Current: 4.63
2.25
9.34
PFCF 9.10
SHPGF's PFCF is ranked higher than
85% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 30.10 vs. SHPGF: 9.10 )
Ranked among companies with meaningful PFCF only.
SHPGF' s PFCF Range Over the Past 10 Years
Min: 9.1  Med: 23.19 Max: 44
Current: 9.1
9.1
44
POCF 7.63
SHPGF's POCF is ranked higher than
86% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 27.83 vs. SHPGF: 7.63 )
Ranked among companies with meaningful POCF only.
SHPGF' s POCF Range Over the Past 10 Years
Min: 7.59  Med: 16.30 Max: 26.82
Current: 7.63
7.59
26.82
EV-to-EBIT 10.37
SHPGF's EV-to-EBIT is ranked higher than
68% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. SHPGF: 10.37 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPGF' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.1  Med: 16.10 Max: 42.6
Current: 10.37
-16.1
42.6
EV-to-EBITDA 8.81
SHPGF's EV-to-EBITDA is ranked higher than
69% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 15.20 vs. SHPGF: 8.81 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPGF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.3  Med: 12.90 Max: 28.6
Current: 8.81
-21.3
28.6
PEG 0.39
SHPGF's PEG is ranked higher than
93% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. SHPGF: 0.39 )
Ranked among companies with meaningful PEG only.
SHPGF' s PEG Range Over the Past 10 Years
Min: 0.61  Med: 0.94 Max: 2.45
Current: 0.39
0.61
2.45
Shiller P/E 44.39
SHPGF's Shiller P/E is ranked higher than
51% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 45.29 vs. SHPGF: 44.39 )
Ranked among companies with meaningful Shiller P/E only.
SHPGF' s Shiller P/E Range Over the Past 10 Years
Min: 44.39  Med: 112.44 Max: 469
Current: 44.39
44.39
469
Current Ratio 0.63
SHPGF's Current Ratio is ranked lower than
92% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. SHPGF: 0.63 )
Ranked among companies with meaningful Current Ratio only.
SHPGF' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.76 Max: 7.43
Current: 0.63
0.52
7.43
Quick Ratio 0.49
SHPGF's Quick Ratio is ranked lower than
92% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SHPGF: 0.49 )
Ranked among companies with meaningful Quick Ratio only.
SHPGF' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.53 Max: 7.07
Current: 0.49
0.4
7.07
Days Inventory 225.37
SHPGF's Days Inventory is ranked lower than
84% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. SHPGF: 225.37 )
Ranked among companies with meaningful Days Inventory only.
SHPGF' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 181.33 Max: 244.29
Current: 225.37
126.5
244.29
Days Sales Outstanding 75.56
SHPGF's Days Sales Outstanding is ranked lower than
70% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. SHPGF: 75.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPGF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 68.62 Max: 75.29
Current: 75.56
47.71
75.29
Days Payable 122.26
SHPGF's Days Payable is ranked higher than
79% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. SHPGF: 122.26 )
Ranked among companies with meaningful Days Payable only.
SHPGF' s Days Payable Range Over the Past 10 Years
Min: 80.31  Med: 110.24 Max: 161.12
Current: 122.26
80.31
161.12

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.46
SHPGF's Dividend Yield is ranked lower than
86% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. SHPGF: 0.46 )
Ranked among companies with meaningful Dividend Yield only.
SHPGF' s Dividend Yield Range Over the Past 10 Years
Min: 0.23  Med: 0.42 Max: 0.7
Current: 0.46
0.23
0.7
Dividend Payout 0.04
SHPGF's Dividend Payout is ranked higher than
99% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. SHPGF: 0.04 )
Ranked among companies with meaningful Dividend Payout only.
SHPGF' s Dividend Payout Range Over the Past 10 Years
Min: 0.05  Med: 0.25 Max: 1.23
Current: 0.04
0.05
1.23
Dividend Growth (3y) 16.00
SHPGF's Dividend Growth (3y) is ranked higher than
77% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. SHPGF: 16.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SHPGF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 13.45 Max: 57.9
Current: 16
0
57.9
Forward Dividend Yield 0.17
SHPGF's Forward Dividend Yield is ranked lower than
86% of the 217 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. SHPGF: 0.17 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.98
SHPGF's Yield on cost (5-Year) is ranked lower than
68% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. SHPGF: 0.98 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPGF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.49  Med: 0.90 Max: 1.5
Current: 0.98
0.49
1.5
3-Year Average Share Buyback Ratio 0.20
SHPGF's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: -9.90 vs. SHPGF: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPGF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.8  Med: -2.60 Max: 1.4
Current: 0.2
-28.8
1.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.06
SHPGF's Price/Projected FCF is ranked higher than
88% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 2.91 vs. SHPGF: 1.06 )
Ranked among companies with meaningful Price/Projected FCF only.
SHPGF' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.25  Med: 2.10 Max: 3.47
Current: 1.06
1.25
3.47
Price/Median PS Value 1.08
SHPGF's Price/Median PS Value is ranked lower than
63% of the 846 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. SHPGF: 1.08 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPGF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.55  Med: 1.00 Max: 2.54
Current: 1.08
0.55
2.54
Price/Peter Lynch Fair Value 0.39
SHPGF's Price/Peter Lynch Fair Value is ranked higher than
94% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 1.73 vs. SHPGF: 0.39 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPGF' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.72  Med: 1.27 Max: 2.92
Current: 0.39
0.72
2.92
Earnings Yield (Greenblatt) (%) 9.68
SHPGF's Earnings Yield (Greenblatt) (%) is ranked higher than
82% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. SHPGF: 9.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SHPGF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 5.60 Max: 9.68
Current: 9.68
2.3
9.68
Forward Rate of Return (Yacktman) (%) 34.03
SHPGF's Forward Rate of Return (Yacktman) (%) is ranked higher than
63% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. SHPGF: 34.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SHPGF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.5  Med: 2.40 Max: 35.6
Current: 34.03
1.5
35.6

More Statistics

Revenue(Mil) $6298
EPS $ 5.41
Beta1.67
Short Percentage of Float0.00%
52-Week Range $49.09 - 88.25
Shares Outstanding(Mil)600.61

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 6,189 6,873 7,542 8,951
EPS($) 4.06 4.55 4.81 6.08
EPS without NRI($) 4.06 4.55 4.81 6.08

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:S7E.Germany, SHPG N.Mexico, SHP.UK, SHPG.USA,
Shire PLC was registered in Jersey on 28th January, 2008. It is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs. The Company unified its business during 2013 by integrating the operations of the Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT) and Regenerative Medicine (RM) business units into a simplified One Shire organization. The Company has four commercial units that focus exclusively on the commercial execution of its In-Line products in the following specialist therapeutic areas: Rare Diseases, Neuroscience, Gastrointestinal (GI) and Internal Medicine. The clinical development, manufacturing and marketing of the Company's products is subject to governmental regulation in the US, the EU and other territories.
» More Articles for SHPGF

Headlines

Articles On GuruFocus.com
Tweedy Browne Fund 4th Quarter Commentary Jan 27 2016 
John Paulson Sells Stake in Broadcom, Cuts Cablevision Holding Nov 18 2015 
Undervalued Baxalta Shares Target of Acquisition by Shire Plc Aug 05 2015 
Manning & Napier's Top 5 New Stock Buys of Q2 Jul 09 2015 
Manning & Napier Invests in Stake in Baidu Jul 08 2015 
Invesco European Growth Fund Parts With Two Stakes Jul 01 2015 
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
John Paulson's Stocks Trading at Low P/E May 04 2015 

More From Other Websites
Are City Analysts Wrong About Shire PLC, easyJet plc And International Consolidated Airlns Grp SA? Feb 12 2016
Are City Analysts Wrong About Shire PLC, easyJet plc And International Consolidated Airlns Grp SA? Feb 12 2016
[$$] Shire calls halt to $50bn acquisition spree Feb 11 2016
Drugmaker Shire delivers earnings beat amid deal-making push Feb 11 2016
Drugmaker Shire delivers earnings beat amid deal-making push Feb 11 2016
[$$] Shire's Net Income Drops Sharply in Fourth Quarter Feb 11 2016
Shire Fourth-Quarter Earnings Exceed Analysts' Expectation Feb 11 2016
RBC Upgrades Shire To Outperform, Says Market Overestimating Competition Feb 10 2016
Why I'd Buy GlaxoSmithKline plc Over Smith & Nephew plc And Shire PLC Feb 08 2016
Shire's NDA Resubmission for Lifitegrast Accepted by FDA Feb 05 2016
Pharma firm gets FDA approval for ADHD drug, more jobs likely Jan 28 2016
The Baxalta–Shire merger: Basics of Shire Pharmaceuticals Jan 26 2016
Shire stays mum on Burlington facilities, employees in wake of Dyax acquisition Jan 25 2016
Will Professional Arbitrageurs Set up the Baxalta–Shire Spread? Jan 22 2016
The Baxalta–Shire Deal’s Risk-to-Reward Ratio Is around 1:1 Jan 19 2016
Why Baxalta Inc (BXLT) Is A Sell Now For Dividend Growth Investors Jan 19 2016
JPM 2016: Fear And Loathing In Healthcare From San Francisco Jan 19 2016
Britain's FTSE sags as commodities concerns weigh Jan 18 2016
[$$] Purchase of Baxalta Is Right Rx for Shire Jan 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK